RxDoctor Payments Data

Hernan Gonzalez

Family · Deltona, FLNPI 1497272603

Payments from drug & device makers

$784in general payments, 2019–2025

Across 24 payments — averaging $32.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$431
  • Novo Nordisk$106
  • AbbVie$66
  • Lilly USA, LLC$65
  • Corcept Therapeutics$47
  • Eli Lilly Export S.A. Puerto Rico Branch$22
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$784 in reported general payments places this provider in the 65th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$9,649
Medicare patients
58
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$16,752
LinzessLinaclotide14$11,768
EliquisApixaban18$11,304
FarxigaDapagliflozin Propanediol12$7,704
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$2,095
Gabapentin64$738
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic11$721
Rosuvastatin Calcium35$635
FenofibrateFenofibrate Nanocrystallized22$603
Albuterol Sulfate HfaAlbuterol Sulfate22$523
Atorvastatin Calcium44$514
Quetiapine Fumarate24$481
Lisinopril49$469
Diclofenac Sodium28$462
Levothyroxine Sodium37$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$106$16,75217 claims
AbbVieLinzess$66$11,76814 claims
AstraZenecaFarxiga$431$7,70412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 14,618 family providers in Florida.

Other family in Deltona

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →